SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Lux Amber, Corp. – ‘10-Q’ for 1/31/22

On:  Wednesday, 5/25/22, at 3:42pm ET   ·   For:  1/31/22   ·   Accession #:  1683168-22-4005   ·   File #:  0-56207

Previous ‘10-Q’:  ‘10-Q’ on 12/17/21 for 10/31/21   ·   Latest ‘10-Q’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/25/22  Lux Amber, Corp.                  10-Q        1/31/22   54:3.2M                                   GlobalOne Filings Inc/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    567K 
 2: EX-31.1     Rule 13A-14(A)/15D-14(A) - Certification            HTML     20K 
 3: EX-31.2     Rule 13A-14(A)/15D-14(A) - Certification            HTML     20K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     16K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     16K 
11: R1          Cover                                               HTML     67K 
12: R2          Condensed Consolidated Balance Sheets (Unaudited)   HTML    131K 
13: R3          Condensed Consolidated Balance Sheets (Unaudited)   HTML     24K 
                (Parenthetical)                                                  
14: R4          Condensed Consolidated Statements of Operations     HTML     74K 
                (Unaudited)                                                      
15: R5          Condensed Consolidated Statements Changes in        HTML     82K 
                Stockholders' Equity (Unaudited)                                 
16: R6          Condensed Consolidated Statements of Cash Flows     HTML     91K 
                (Unaudited)                                                      
17: R7          Nature of Business                                  HTML     20K 
18: R8          Summary of Significant Accounting Policies          HTML     56K 
19: R9          Accounts Receivable                                 HTML     20K 
20: R10         Notes Payable                                       HTML     54K 
21: R11         Accrued Expenses                                    HTML     22K 
22: R12         Commitments, Contingencies and Concentrations       HTML     32K 
23: R13         Stockholders? Equity                                HTML     72K 
24: R14         Related Party Transactions                          HTML     27K 
25: R15         Income Taxes                                        HTML     28K 
26: R16         Corona Virus                                        HTML     24K 
27: R17         Subsequent Events                                   HTML     20K 
28: R18         Summary of Significant Accounting Policies          HTML     99K 
                (Policies)                                                       
29: R19         Summary of Significant Accounting Policies          HTML     22K 
                (Tables)                                                         
30: R20         Accounts Receivable (Tables)                        HTML     20K 
31: R21         Notes Payable (Tables)                              HTML     20K 
32: R22         Accrued Expenses (Tables)                           HTML     21K 
33: R23         Commitments, Contingencies and Concentrations       HTML     23K 
                (Tables)                                                         
34: R24         Stockholders? Equity (Tables)                       HTML     41K 
35: R25         Income Taxes (Tables)                               HTML     23K 
36: R26         Summary of Significant Accounting Policies          HTML     25K 
                (Details - Inventory)                                            
37: R27         Summary of Significant Accounting Policies          HTML     39K 
                (Details Narrative)                                              
38: R28         Accounts Receivable (Details)                       HTML     18K 
39: R29         Notes Payable (Details - Minimum debt payments)     HTML     25K 
40: R30         Notes Payable (Details Narrative)                   HTML    119K 
41: R31         Accrued Expenses (Details)                          HTML     22K 
42: R32         Commitmentscontingencies and Concentrations         HTML     33K 
                (Details - Minimum Lease payments)                               
43: R33         Commitments, Contingencies and Concentrations       HTML     37K 
                (Details Narrative)                                              
44: R34         Stockholders' Equity (Details - Option activity)    HTML     52K 
45: R35         Stockholders' Equity (Details - Fair value          HTML     27K 
                assumption)                                                      
46: R36         Stockholders? Equity (Details Narrative)            HTML     68K 
47: R37         Related Party Transactions (Details Narrative)      HTML     34K 
48: R38         Income Taxes (Details - Income tax reconciliation)  HTML     26K 
49: R39         Corona Virus (Details Narrative)                    HTML     25K 
52: XML         IDEA XML File -- Filing Summary                      XML     90K 
50: XML         XBRL Instance -- lux_i10q-013122_htm                 XML    669K 
51: EXCEL       IDEA Workbook of Financial Reports                  XLSX     59K 
 7: EX-101.CAL  XBRL Calculations -- lxam-20220131_cal               XML    135K 
 8: EX-101.DEF  XBRL Definitions -- lxam-20220131_def                XML    237K 
 9: EX-101.LAB  XBRL Labels -- lxam-20220131_lab                     XML    637K 
10: EX-101.PRE  XBRL Presentations -- lxam-20220131_pre              XML    476K 
 6: EX-101.SCH  XBRL Schema -- lxam-20220131                         XSD     94K 
53: JSON        XBRL Instance as JSON Data -- MetaLinks              259±   340K 
54: ZIP         XBRL Zipped Folder -- 0001683168-22-004005-xbrl      Zip    105K 


‘10-Q’   —   Quarterly Report

Document Table of Contents

Page (sequential)   (alphabetic) Top
 
11st Page  –  Filing Submission
"Table of Contents
"Part I. Financial Information
"Condensed Consolidated Financial Statements
"Management's Discussion and Analysis of Financial Condition and Results of Operations
"Controls and Procedures
"Part Ii. Other Information
"Legal Proceedings
"Risk Factors
"Unregistered Sales of Equity Securities and Use of Proceeds
"Defaults Upon Senior Securities
"Mine Safety Disclosures
"Other Information
"Exhibits
"Signatures

This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0001740695  i false  i 04/30  i 2022  i Q3  i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i   i  0001740695 2021-05-01 2022-01-31 0001740695 2022-04-28 0001740695 2022-01-31 0001740695 2021-04-30 0001740695 2021-11-01 2022-01-31 0001740695 2020-11-01 2021-01-31 0001740695 2020-05-01 2021-01-31 0001740695 us-gaap:CommonStockMember 2021-10-31 0001740695 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001740695 us-gaap:RetainedEarningsMember 2021-10-31 0001740695 us-gaap:NoncontrollingInterestMember 2021-10-31 0001740695 2021-10-31 0001740695 us-gaap:CommonStockMember 2020-10-31 0001740695 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001740695 us-gaap:RetainedEarningsMember 2020-10-31 0001740695 us-gaap:NoncontrollingInterestMember 2020-10-31 0001740695 2020-10-31 0001740695 us-gaap:CommonStockMember 2021-04-30 0001740695 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001740695 us-gaap:RetainedEarningsMember 2021-04-30 0001740695 us-gaap:NoncontrollingInterestMember 2021-04-30 0001740695 us-gaap:CommonStockMember 2020-04-30 0001740695 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0001740695 us-gaap:RetainedEarningsMember 2020-04-30 0001740695 us-gaap:NoncontrollingInterestMember 2020-04-30 0001740695 2020-04-30 0001740695 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0001740695 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0001740695 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0001740695 us-gaap:NoncontrollingInterestMember 2021-11-01 2022-01-31 0001740695 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001740695 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001740695 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001740695 us-gaap:NoncontrollingInterestMember 2020-11-01 2021-01-31 0001740695 us-gaap:CommonStockMember 2021-05-01 2022-01-31 0001740695 us-gaap:AdditionalPaidInCapitalMember 2021-05-01 2022-01-31 0001740695 us-gaap:RetainedEarningsMember 2021-05-01 2022-01-31 0001740695 us-gaap:NoncontrollingInterestMember 2021-05-01 2022-01-31 0001740695 us-gaap:CommonStockMember 2020-05-01 2021-01-31 0001740695 us-gaap:AdditionalPaidInCapitalMember 2020-05-01 2021-01-31 0001740695 us-gaap:RetainedEarningsMember 2020-05-01 2021-01-31 0001740695 us-gaap:NoncontrollingInterestMember 2020-05-01 2021-01-31 0001740695 us-gaap:CommonStockMember 2022-01-31 0001740695 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001740695 us-gaap:RetainedEarningsMember 2022-01-31 0001740695 us-gaap:NoncontrollingInterestMember 2022-01-31 0001740695 us-gaap:CommonStockMember 2021-01-31 0001740695 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001740695 us-gaap:RetainedEarningsMember 2021-01-31 0001740695 us-gaap:NoncontrollingInterestMember 2021-01-31 0001740695 2021-01-31 0001740695 us-gaap:WarrantMember 2021-05-01 2022-01-31 0001740695 us-gaap:WarrantMember 2020-05-01 2021-01-31 0001740695 us-gaap:StockOptionMember 2021-05-01 2022-01-31 0001740695 us-gaap:StockOptionMember 2020-05-01 2021-01-31 0001740695 LXAM:ConvertibleDebentures1Member 2021-04-30 0001740695 LXAM:ConvertibleDebentures1Member 2020-05-01 2021-04-30 0001740695 LXAM:ConvertibleDebentures2Member 2021-04-30 0001740695 LXAM:ConvertibleDebentures2Member 2020-05-01 2021-04-30 0001740695 LXAM:ConvertibleDebentures2Member 2021-05-02 0001740695 LXAM:VehicleNotePayableMember 2022-01-31 0001740695 LXAM:VehicleNotePayableMember 2021-04-30 0001740695 LXAM:PaycheckProtectionProgramMember LXAM:SBAMember 2020-03-01 2020-03-08 0001740695 LXAM:PaycheckProtectionProgramMember LXAM:SBAMember 2020-05-08 0001740695 LXAM:PaycheckProtectionProgramMember 2020-11-01 2020-11-30 0001740695 LXAM:PromissoryNoteMember LXAM:AnInvestorMember 2021-02-01 2021-02-02 0001740695 LXAM:PromissoryNoteMember LXAM:AnInvestorMember 2021-02-02 0001740695 LXAM:PromissoryNoteMember LXAM:AnInvestorMember 2020-05-01 2021-04-30 0001740695 LXAM:PromissoryNoteMember LXAM:AnInvestorMember 2021-05-01 2022-01-31 0001740695 LXAM:PaycheckProtectionProgramMember 2021-02-10 2021-02-11 0001740695 LXAM:PaycheckProtectionProgramMember 2021-02-11 0001740695 LXAM:PaycheckProtectionProgramMember 2021-02-13 2021-02-14 0001740695 LXAM:PaycheckProtectionProgramMember 2021-02-14 0001740695 LXAM:PaycheckProtectionProgramMember 2021-03-15 2021-03-16 0001740695 LXAM:PaycheckProtectionProgramMember 2021-03-16 0001740695 LXAM:PromissoryNote1Member LXAM:AnInvestorMember 2021-04-18 2021-04-19 0001740695 LXAM:PromissoryNote1Member LXAM:AnInvestorMember 2021-04-19 0001740695 LXAM:PromissoryNote2Member LXAM:AnInvestorMember 2021-05-09 2021-05-10 0001740695 LXAM:PromissoryNote2Member LXAM:AnInvestorMember 2021-05-10 0001740695 LXAM:PromissoryNote3Member LXAM:AnInvestorMember 2021-05-18 2021-05-19 0001740695 LXAM:PromissoryNote3Member LXAM:AnInvestorMember 2021-05-19 0001740695 LXAM:PromissoryNote4Member LXAM:AnInvestorMember 2021-06-06 2021-06-07 0001740695 LXAM:PromissoryNote4Member LXAM:AnInvestorMember 2021-06-07 0001740695 LXAM:PromissoryNote5Member LXAM:AnInvestorMember 2021-06-06 2021-06-07 0001740695 LXAM:PromissoryNote5Member LXAM:AnInvestorMember 2021-06-07 0001740695 LXAM:PromissoryNote5Member LXAM:AnInvestorMember 2022-01-31 0001740695 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember LXAM:FourCustomerMember 2021-05-01 2022-01-31 0001740695 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember LXAM:FourCustomerMember 2020-05-01 2021-04-30 0001740695 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember LXAM:TwoCustomerMember 2021-05-01 2022-01-31 0001740695 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember LXAM:TwoCustomerMember 2020-05-01 2021-01-31 0001740695 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember LXAM:ThreeCustomerMember 2021-11-01 2022-01-31 0001740695 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember LXAM:TwoCustomerMember 2020-11-01 2021-01-31 0001740695 LXAM:CommonStock1Member 2020-05-01 2021-01-31 0001740695 LXAM:StockPlan2016Member 2017-02-02 0001740695 us-gaap:StockOptionMember 2021-05-01 2022-01-31 0001740695 2019-11-01 2020-01-31 0001740695 us-gaap:StockOptionMember 2021-04-30 0001740695 us-gaap:StockOptionMember 2020-05-01 2021-04-30 0001740695 us-gaap:StockOptionMember 2022-01-31 0001740695 us-gaap:StockOptionMember 2020-04-30 0001740695 us-gaap:StockOptionMember 2019-05-01 2020-04-30 0001740695 us-gaap:StockOptionMember 2020-05-01 2021-01-31 0001740695 us-gaap:StockOptionMember 2021-01-31 0001740695 LXAM:FiveShareholdersMember 2021-05-01 2022-01-31 0001740695 LXAM:FiveShareholdersMember 2020-05-01 2021-01-31 0001740695 LXAM:FiveShareholdersMember 2022-01-31 0001740695 LXAM:FiveShareholdersMember 2021-01-31 0001740695 LXAM:FourShareholdersMember 2021-11-01 2022-01-31 0001740695 LXAM:FourShareholdersMember 2020-11-01 2021-01-31 0001740695 LXAM:FourShareholdersMember 2022-01-31 0001740695 LXAM:FourShareholdersMember 2021-01-31 0001740695 LXAM:VehicleRental1Member 2021-05-01 2022-01-31 0001740695 LXAM:VehicleRental2Member 2021-05-01 2022-01-31 0001740695 LXAM:VehicleRental1Member 2020-11-01 2021-01-31 0001740695 LXAM:VehicleRental2Member 2020-11-01 2021-01-31 0001740695 LXAM:PaycheckProtectionProgramMember LXAM:SBAMember 2020-05-02 2020-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM  i 10-Q

 

 i  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED:  i January 31, 2022

 

OR

 

 i  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from__________ to __________

 

COMMISSION FILE NUMBER:  i 000-56207

 

 i Lux Amber, Corp.

(Exact name of registrant as specified in its charter)

 

 i Nevada 000-55554  i 98-1414834
(State or other jurisdiction
of incorporation or organization)
(Commission
File No.)
(IRS Employee
Identification No.)

 

 i 371 Hostdale Drive

 i Dothan,  i AL  i 36303

(Address of Principal Executive Offices)

 

 i 214- i 676-5475

(Issuer Telephone number)

 

6136 Frisco Square Blvd.

Suite 400, #237

Frisco, TX 75034

(Former Address)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
 i Common Stock  i LXAM N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   i Yes ☒        No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☐         i No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated Filer ☐
 i Non-accelerated filer Smaller reporting company  i 
Emerging Growth Company  i   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ☐         i No  ☒

 

The number of Registrant’s shares of common stock, $0.0001 par value, outstanding as of April 28, 2022, was  i 34,910,511.


 C: 
  C:   

 

 

TABLE OF CONTENTS

 

    Page
     
PART I.  FINANCIAL INFORMATION 3
     
  Item 1 Condensed Consolidated Financial Statements 3
       
  Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations 20
       
  Item 4 Controls and Procedures 22
       
PART II.  OTHER INFORMATION 23
     
  Item 1 Legal Proceedings 23
       
  Item 1A Risk Factors 23
       
  Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 23
       
  Item 3 Defaults Upon Senior Securities 23
       
  Item 4 Mine Safety Disclosures 23
       
  Item 5 Other Information 23
       
  Item 6 Exhibits 24
       
SIGNATURES 25

 

 

 

 

 

 

 C: 
  C: 2 

 

 

PART 1 - FINANCIAL INFORMATION

 

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

LUX AMBER, CORP. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

     

         
   January 31, 2022   April 30, 2021 
   (Unaudited)   (Audited) 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $ i 27,480   $ i  
Accounts receivable    i 45,279     i 112,982 
Inventory    i 16,103     i 137,211 
Prepaid expenses    i 4,967     i 2,000 
Other current assets    i      i 5,960 
Total current assets    i 93,829     i 258,153 
           
GOODWILL    i 2,294,953     i 2,294,953 
           
OTHER INTANGIBLES    i 15,000     i 15,000 
           
OTHER LONG-TERM ASSETS    i 18,270     i  
           
FIXED ASSETS          
Furniture, fixtures, and office equipment    i 36,096     i 36,256 
Vehicles and trailers    i 285,985     i 284,650 
Equipment    i 676,686     i 649,910 
Leasehold improvements    i 12,190     i 12,190 
Assets in process    i 10,581     i 14,259 
 TOTAL FIXED ASSETS    i 1,021,538     i 997,265 
Accumulated depreciation   ( i 587,428)   ( i 484,568)
Fixed assets, net    i 434,110     i 512,697 
           
RIGHT OF USE ASSETS    i 294,814     i 272,657 
           
TOTAL ASSETS  $ i 3,150,976   $ i 3,353,460 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
           
CURRENT LIABILITIES          
Accounts payable  $ i 676,418   $ i 554,588 
Accrued expenses    i 1,677,706     i 1,201,568 
Related party payables    i 211,442     i 208,756 
Notes payable – current portion    i 21,076     i 112,889 
Right of use liabilities – current portion    i 182,013     i 172,498 
Total current liabilities    i 2,768,655     i 2,250,299 
           
NON-CURRENT LIABILITIES          
Notes payable    i      i 14,735 
Right of use liabilities    i 101,316     i 98,761 
Paycheck Protection Program loans    i 104,752     i 104,752 
TOTAL LIABILITIES    i 2,974,723     i 2,468,547 
           
STOCKHOLDERS’ EQUITY          
           
Common stock, $ i  i 0.0001 /  par value,  i  i 75,000,000 /  shares authorized:  i  i 33,394,678 /  issued and outstanding shares as of January 31, 2022, and  i  i 31,111,658 /  issued and outstanding shares as of April 30, 2021    i 3,391     i 3,107 
Additional paid-in capital    i 16,799,405     i 15,750,430 
Accumulated deficit   ( i 16,626,543)   ( i 14,868,624)
TOTAL EQUITY    i 176,253     i 884,913 
           
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $ i 3,150,976   $ i 3,353,460 

 

The accompanying footnotes are an integral part of these consolidated financial statements.

 

 

 

 C: 
 3 

 

 

LUX AMBER, CORP. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

     

 

                 
  

Three months

ended

January 31, 2022

  

Three months

ended

January 31, 2021

  

Nine months

ended

January 31, 2022

  

Nine months

ended

January 31, 2021

 
                 
Revenue  $ i 248,944   $ i 130,183   $ i 1,112,022   $ i 816,598 
Cost of goods sold    i 270,800     i 108,695     i 740,442     i 534,149 
Gross Profit (Loss)   ( i 21,856)    i 21,488     i 371,580     i 282,449 
                     
Product delivery expenses    i 15,475     i 103,629     i 24,629     i 404,895 
General and administrative expenses    i 874,730     i 10,547     i 1,944,324     i 1,038,304 
Selling expenses    i 6,683     i 34,695     i 11,607     i 70,450 
Depreciation and amortization    i 91,884     i 39,624     i 109,362     i 114,591 
                     
Total operating expenses    i 988,772     i 188,495     i 2,089,921     i 1,628,240 
                     
Loss from operations   ( i 1,010,628)   ( i 167,007)   ( i 1,718,341)   ( i 1,345,791)
                     
Other expenses                    
Interest expense    i 18,370     i 29,673     i 34,755     i 52,968 
Other expense    i      i 118,268     i 4,823     i 114,988 
Total other expense    i 18,370     i 147,941     i 39,578     i 167,956 
                     
Net loss  $( i 1,028,998)  $( i 314,948)  $( i 1,757,919)  $( i 1,513,747)
                     
Loss per common share:                    
Basic and diluted  $( i 0.03)  $( i 0.01)  $( i 0.05)  $( i 0.05)
                     
Weighted Average Number of Common Shares Outstanding:                    
Basic and diluted    i 31,794,579     i 30,958,663     i 33,394,678     i 30,389,570 

 

 

The accompanying footnotes are an integral part of these condensed consolidated financial statements.

 

 

 

 

 

 C: 
 4 

 

 

LUX AMBER, CORP. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

 

For the Three Months Ended January 31, 2022 and January 31, 2021

 

 

                             
  

Number of

Shares

Issued and

Outstanding

  

Common

Stock

Par Value

Amount

  

Additional

Paid-in

Capital

  

Accumulated

Deficit

           Total 
Balance as of October 31, 2021    i 31,111,658   $ i 3,273   $ i 16,181,303   $( i 15,597,545)        $ i 587,031 
Common stock sold    i 900,000     i 50     i 162,500                 i 162,550 
Options exercised for outstanding payables    i 683,020     i 68     i 215,687                 i 215,755 
Shares issued for previous options exercised    i 700,000                         
Stock based compensation            i 239,915                 i 239,915 
Net loss               ( i 1,028,998)         ( i 1,028,998)
Balance as of January 31, 2022    i 33,394,678   $ i 3,391   $ i 16,799,405   $( i 16,626,543)          $ i 176,253 

 

 

  

Number of

Shares

Issued and Outstanding

  

Common

Stock

Par Value

Amount

  

Additional

Paid-in

Capital

  

Accumulated

Deficit

           Total 
Balance as of October 31, 2020    i 30,944,742   $ i 3,073   $ i 15,477,714   $( i 14,083,226)        $ i 1,397,561 
Notes payable with interest converted    i 146,916     i 15     i 183,629                 i 183,644 
Share based compensation            i 44,553                 i 44,553 
Net loss               ( i 314,948)         ( i 314,948)
Balance as of January 31, 2021    i 31,091,658   $ i 3,088   $ i 15,705,896   $( i 14,398,174)          $ i 1,310,811 

 

The accompanying footnotes are an integral part of these condensed consolidated financial statements

 

 

 

 

 

 

 C: 
 5 

 

 

LUX AMBER, CORP. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

 

For the Nine Months Ended January 31, 2022 and January 31, 2021

 

  

Number of

Shares

Issued and Outstanding

  

Common

Stock

Par Value

Amount

  

Additional

Paid-in

Capital

  

Accumulated

Deficit

           Total 
Balance as of April 30, 2021    i 31,111,658   $ i 3,107   $ i 15,750,430   $( i 14,868,624)        $ i 884,913 
Options exercised (cashless)        i 60    ( i 60)              
Shares issued for previous options exercised    i 700,000                         
Options exercised        i 40     i 3,960                 i 4,000 
Common stock sold    i 900,000     i 110     i 412,440                 i 457,550 
Options exercised for outstanding payables    i 683,020     i 74     i 235,681                 i 280,755 
Stock based compensation            i 396,954                 i 396,954 
Net loss               ( i 1,757,919)         ( i 1,757,919)
Balance as of January 31, 2022    i 33,394,678   $ i 3,391   $ i 16,799,405   $( i 16,626,543)        $ i 176,253)

 

  

Number of

Shares
Issued and
Outstanding

  

Common

Stock

Par Value

Amount

  

Additional

Paid-in

Capital

   Accumulated
Deficit
   Non-Controlling Interest   Total 
Balance as of April 30, 2020    i 29,441,708   $ i 2,943   $ i 14,095,093   $( i 12,884,427)  $ i 1,027   $ i 1,214,636 
Common stock repurchased   ( i 36,250)   ( i 5)   ( i 45,308)           ( i 45,313)
Notes payable with interest converted    i 1,686,467)    i 150     i 1,507,265             i 1,507,415 
Dissolution of PCNM                   ( i 1,027)   ( i 1,027)
Adjustments   ( i 267)        i 133,659             i 133,659 
Share based compensation            i 15,187             i 15,187 
Net loss               ( i 1,513,747)       ( i 1,513,747)
Balance as of January 31, 2021    i 31,091,658   $ i 3,088   $ i 15,705,896   $( i 14,398,174)  $   $ i 1,310,811 

 

 

The accompanying footnotes are an integral part of these condensed consolidated financial statements.

 

 

 

 

 C: 
 6 

 

 

LUX AMBER, CORP. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

         
   For the Nine Months Ended January 31, 2022   For the Nine Months Ended January 31, 2021 
Cash Flows from Operating Activities          
Net loss  $( i 1,757,919)  $( i 1,513,747)
Depreciation and amortization    i 109,362     i 241,788 
Share based compensation    i 396,954     i 133,659 
Non-cash interest    i 2,426     i  
Right of use amortization    i 116,894     i 11,898 
Accounts receivable - trade    i 67,703     i 67,602 
Inventory    i 121,108    ( i 25,413)
Prepaid expenses    i      i 6,711 
Other current assets   ( i 15,277)   ( i 37,062)
Accounts payable and accrued expenses    i 528,845     i 648,948 
Due to related parties    i 2,686    ( i 37,542)
Net cash used in operating activities   ( i 427,219)   ( i 503,158)
           
Cash Flows from Investing Activities          
Expenditures for fixed assets   ( i 30,775)   ( i 103,065)
Total cash used in investing activities   ( i 30,775)   ( i 103,065)
           
Cash Flows from Financing Activities          
Proceeds from stock sales    i 412,550     i 730,300 
Payments on notes payable   ( i 11,793)   ( i 8,854)
Proceeds on notes payable    i 121,000    ( i 119,097)
Proceeds from PPP loans    i      i 104,752 
Proceeds from stock option exercises    i 4,000    ( i 45,313)
Payments on capital lease obligations   ( i 40,284)    i  
Net cash provided by financing activities    i 485,473     i 557,036 
           
Net change in cash and cash equivalents    i 27,480    ( i 49,185)
           
Cash at beginning of period    i      i 49,185 
           
Cash at end of period  $ i 27,480   $ i  
           
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION          
Cash paid during period for:          
Interest  $ i 18,370   $ i 32,057 
Taxes  $ i    $ i  
Noncash Financing Activities          
Convertible notes and accrued interest converted to common stock  $ i    $( i 1,507,415)
Stock issued for reduction of outstanding payables  $ i 235,755   $ i  
Right of use lease additions  $ i 137,397   $ i  

 

The accompanying footnotes are an integral part of these consolidated financial statements.

 

 

 

 C: 
 7 

 

 

LUX AMBER, CORP. AND SUBSIDIARIES

 

Notes to Condensed Consolidated Financial Statements

 

January 31, 2022

(Unaudited)

 

 

 i 

NATURE OF BUSINESS

 

Lux Amber, Corp. (“LAC”), formed on January 19, 2018, is an international specialty chemical company. Its corporate offices are currently located at 371 Hostdale Drive, Dothan, AL 36303. LAC’s corporate telephone number is 214-676-5475. LAC has a stock symbol of LXAM.

 

LAC has three (3) wholly owned subsidiaries (collectively with LAC, the “Company”): Worldwide Specialty Chemicals, Inc. (“WSCI”), Industrial Chem Solutions, Inc. (“ICS”), and Safeway Pest Elimination, LLC, (“SPE”), which was formed July 16, 2018. LAC and its subsidiaries serve as both producers and distributors of environmentally safe, specialty chemicals.

 

The Company’s products utilize all-natural and renewable resources, contain no dangerous chemicals or additives, and offer “green” solutions to its customers. ICS’ product line includes asphalt release agents, industrial cleaners, environmental remediation gels, odor control agents, and consumer friendly cleaners for a wide range of uses, including construction, environmental remediation, hazardous materials clean-up, nuclear decommissioning, industrial cleaning, and odor control. SPE’s products are designed for the elimination and control of pests.

 

 i 

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

A summary of the significant accounting polices consistently applied in the preparation of the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (GAAP) is as follows.

 

 i 

Basis of Consolidation

 

The condensed consolidated financial statements include the accounts of LAC, WSCI, ICS, and SPE. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

 i 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

 i 

Fair Value of Financial Instruments

 

FASB ASC 825-10 requires disclosure of fair value information about certain financial instruments, including, but not limited to, cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, related party payables, notes payable, and Paycheck Protection Program loans. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management on January 31, 2022 and April 30, 2021. The carrying value of the financial instruments included in the Company’s consolidated financial statements approximated their fair values.

  

 

 

 

 C: 
 8 

 

 

The carrying value of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at, or approximate, fair value as of the reporting date because of their short-term nature.

 

The carrying value of the notes payable approximates fair value as they bear market rates of interest.

 

 i 

Basic and Diluted Net Loss Per Share

 

Basic net loss per share is computed using the weighted average number of common shares outstanding. Diluted loss per share has not been presented because there are no dilutive items. Diluted earnings loss per share is based on the assumption that all dilutive stock options, warrants, and convertible debt are converted or exercised by applying the treasury stock method. Under this method, options and warrants are assumed exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Options, warrants and/or convertible debt will have a dilutive effect, during periods of net profit, only when the average market price of the common stock during the period exceeds the exercise or conversion price of the items.

 

For the nine months ended January 31, 2022 and 2021, approximately  i 82,668 and  i 82,668 common stock warrants, respectively, and  i 8,984,750 and  i 6,569,750 common stock options, respectively, were not added to the diluted average shares because inclusion of such warrants and options would be antidilutive.

 

 / 
 i 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an initial maturity of three months or less, when purchased, to be cash equivalents. The Company maintains cash balances at several financial institutions located throughout the United States, which at times may exceed insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

 

 i 

Accounts Receivable and Allowance for Doubtful Accounts

 

Accounts receivables are recorded at invoiced amount and generally do not bear interest. An allowance for doubtful accounts is established, as necessary, based on experience and other factors which, in management's judgment, deserve current recognition in estimating bad debts. Such factors include growth and composition of accounts receivable, the relationship of the allowance for doubtful accounts to accounts receivable, and current economic conditions. The determination of the collectability of amounts due requires the Company to make judgments regarding future events and trends. Allowances for doubtful accounts are determined based on assessing the Company’s portfolio on an individual customer and on an overall basis. This process consists of a review of historical collection experience, current aging status of the customer account, and the financial condition of the Company’s customers. Based on a review of these factors, the Company establishes or adjusts the allowance for specific customers and the accounts receivable portfolio as a whole. On January 31, 2022 and April 30, 2021, the allowance for doubtful accounts was $ i  i 0 / .

 

 / 
 i 

Revenue Recognition

  

Revenue is measured as the amount of consideration expected to be received in exchange for transferring goods or providing service. Revenue from product sold is recognized when obligations with the customer are satisfied, which generally occurs with the transfer or delivery of the product, signifying the point in time when the customer obtains control of the promised goods. Our performance obligation is delivering the product to the customer; and therefore, the transaction price, which is stated on the invoice, is allocated 100% to the sole performance obligation of product delivery. For the three-month and nine-month periods ended January 31, 2022 and 2021, all revenue was from products sold.

 

Our sales policies do not provide for general rights of return, and payment is due net of 15 days. We do not record estimated reductions to revenue for customer programs and incentive offerings including pricing arrangements, promotions, and other volume-based incentives at the time of the sale. We also do not record estimated reserves for product returns and credits at the time of sale and anticipated uncollectible accounts.

 

 

 

 C: 
 9 

 

 

 i 

Sales Taxes

 

Sales (and similar) taxes that are imposed on the Company's sales and collected from customers are excluded from revenues.

 

Shipping and Handling Costs

 

Costs for shipping and handling activities, including those activities that occur after transfer of control to the customer, are recorded as cost of sales and are expensed as incurred. The Company accrues costs for shipping and handling activities that occur after control of the promised good has transferred to the customer.

 

 i 

Inventory

 

Inventory is stated at the lower of cost or net realizable value, with cost determined on a first-in first-out basis. The carrying value of inventory is reduced for estimated obsolescence. The Company evaluates the inventory carrying value for potential excess and obsolete inventory exposures by analyzing historical and anticipated demand.

 

The following table sets forth the components of the Company’s inventory balances as of:

 

 i 
Schedule of inventory        
   January 31,
2022
   April 30,
2021
 
Finished goods  $ i 18,174   $ i 93,203 
Raw materials    i 15,219     i 61,298 
Obsolescence   ( i 17,290)   ( i 17,290)
 Inventory, net  $ i 16,103   $ i 137,211 
 / 

 

 / 
 i 

Fixed Assets

 

Fixed assets consist of furniture, fixtures and office equipment, vehicles and trailers, equipment and leasehold improvements that are stated at cost, less accumulated depreciation. Depreciation is provided in amounts sufficient to relate the cost of depreciable assets to earnings over their estimated service lives (3 – 10 years) under the straight-line method.

 

Maintenance and repairs are charged to earnings as incurred; major repairs and replacements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in operations.

   

 i 

Goodwill

 

Goodwill represents the difference between the enterprise value/cash paid less the fair value of all recognized net asset fair values including identifiable intangible asset values in a business combination. The Company reviews goodwill for impairment annually during the fourth quarter or whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. The Company considered the current and expected future economic and market conditions surrounding COVID-19 and its impact on the reporting unit. As a result of the certain business developments and changes in the Company's long-term projections, during the fourth quarter of fiscal 2021, the Company concluded a triggering event had occurred that required an impairment assessment to be performed. The qualitative assessment thresholds were not met. The Company calculated the quantitative impairment test of using the implied fair market value using market data and concluded there was no goodwill impairment loss. Based on annual testing, the Company determined that there was  i no goodwill impairment in Fiscal 2021. The Company noted no triggering events as of January 31, 2022.

  

 

 

 C: 
 10 

 

 

The Company first evaluates qualitative factors to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of the reporting unit is less than its carrying amount, including goodwill. If after qualitatively assessing the totality of events or circumstances, the Company determines that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount, then further testing is unnecessary. If after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, the Company then estimates the fair value of the reporting unit and compares the fair value of the reporting unit with its carrying amount, including goodwill, as discussed below.

 

The quantitative goodwill impairment test involves a two-step process. In the first step, the Company compares the fair value of each reporting unit to its carrying value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss. In the second step, the reporting unit's fair value is allocated to all of the assets and liabilities of the reporting unit, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the reporting unit was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss.

 

 / 
 i 

Share-Based Compensation

 

The Company recognizes compensation expense for all share-based payments in accordance with FASB Codification Topic 718, Compensation — Stock Compensation, (ASC 718). Under the fair value recognition provisions of ASC 718, the Company recognizes share-based compensation expense, net of an estimated forfeiture rate, over the requisite service period of the award. The fair value at the measurement date of stock options is estimated using the Black-Scholes option-pricing model. Compensation expense is recognized on a straight-line basis over the vesting period based on the estimated number of stock options that are expected to vest.

 

 i 

Income Taxes

 

The Company accounts for Federal and state income taxes using the asset and liability approach for financial accounting and reporting for income taxes based on tax effects of differences between the financial statement and tax basis of assets and liabilities.

 

The Company accounts for all uncertain tax positions in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 740 – Income Taxes (“ASC 740”). ASC 740 provides guidance on de-recognition, classification, interest and penalties and disclosure related to uncertain income tax positions. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. There were no accrued interest or penalties as of January 31, 2022 or April 30, 2021.

 

From time to time, the Company may be audited by taxing authorities. These audits could result in proposed assessments of additional taxes. The Company believes that its tax positions comply in all material respects with applicable tax law. However, tax law is subject to interpretation, and interpretations by taxing authorities could be different from those of the Company, which could result in the imposition of additional taxes. The Company’s federal returns since 2016 are still subject to examination by taxing authorities.

  

 i 

License Fee

 

ICS pays 10% of the net selling price of $9.50 a gallon to CBI Polymers, Inc (“CBI”), as a mutually acceptable license fee. E. Thomas Layton, Chairman and CEO of LAC, is also the Chairman and CEO and controlling shareholder of CBI. During the nine-month ended January 31, 2022 and 2021, the Company incurred $ i 8,780 and $ i 17,510 of license fees to CBI for those sales. During the three-month ended January 31, 2022 and 2021, the Company incurred $ i 8,663 and $ i 12,320 of license fees to CBI for those sales.

 

 

 

 

 C: 
 11 

 

 

 / 
 i 

Advertising Costs

 

The Company recognizes expenses for advertising costs as they are incurred. During the nine months ended January 31, 2022 and 2021, the Company incurred $ i 3,227 and $ i 17,919 in advertising costs. During the three months ended January 31, 2022 and 2021, the Company incurred $ i 393 and $ i 6,022 in advertising costs.

   

 / 
 i 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred substantial operating losses, resulting in an accumulated deficit of $ i 16,626,543 on January 31, 2022. The Company has a working capital deficit of $ i 2,674,826 as of January 31, 2022. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are being issued. Accordingly, the Company is arranging for additional financing to fully implement its business plan, including continued growth and establishment of a stronger brand.

 

The Company is actively seeking growth of its service offerings, both organically and via new client relationships. In the ordinary course of the Company’s business, management is trying to raise additional capital through sales of common stock as well as seeking debt financing from third parties. There are current indications that additional financing will be available on favorable terms. If additional financing is not available, the Company will need to reduce salaries, defer, or cancel development programs, planned initiatives and overhead expenditures. The failure to adequately fund its capital requirements could have a material adverse effect on the Company’s business, financial condition, and results of operations, including potential discontinuance of operations. Moreover, the sale of additional equity securities to raise financing will result in additional dilution to the Company’s stockholders. Additionally, incurring additional indebtedness could involve an increased debt service cash obligation, as well as the imposition of covenants that restrict the Company’s operations or the Company’s ability to perform on its current debt service requirements. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. While the Company recognizes the significant impact of additional financing, the Company is a smaller reporting company serving large and growing markets and it will continue to sell securities and enter into financing programs which are deemed to be prudent.

 

 / 
 i 

Recently Issued Accounting Pronouncements

 

Pronouncements Not Yet Adopted

 

In June 2016, the FASB issued ASU 2016-13 Financial Instruments-Credit Losses, which amends how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income, which applies to trade accounts receivable and the calculation of the allowance for uncollectible accounts receivable. The new standard became effective for the Company for annual and interim periods beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this accounting guidance will have on the consolidated financial statements.

 

 / 
 i 

2. ACCOUNTS RECEIVABLE

 

Accounts receivable relate to trade receivables from product sales made by the Company. Accounts receivable consist of the following at January 31, 2022 and April 30, 2021:

 i 
Schedule of accounts receivable        
   January 31,
2022
   April 30,
2021
 
Trade receivables  $ i 45,279   $ i 112,982 
 / 

  

 

 

 

 C: 
 12 

 

 

 / 
 i 

3. NOTES PAYABLE

 

Convertible Promissory Notes Payable

During the year ended April 30, 2021, the Company issued a fourth round of convertible debentures in the principal amount of $ i 525,500. The debentures were convertible into shares of the Company’s common stock at the maturity date of  i September 15, 2020 and pay any unpaid interest at a rate of  i 8%. The debentures were converted into  i 611,047 shares of common stock at a price of $ i 0.86 per share and the accrued interest unpaid amount of $ i 16,459 was converted into  i 19,138 shares of common stock at a price of $0.86 per share.

 

During the year ended April 30, 2021, the Company issued a fifth round of convertible debentures in the principal amount of $ i 204,800. The debentures were convertible into shares of the Company’s common stock at the maturity date of  i January 15, 2021 and pay any unpaid interest at a rate of  i 8%. This round of debentures was converted  i 163,890 shares of common stock at a price of $ i 1.25 per share and accrued interest of $ i 2,074 was converted into  i 1,660 shares of common stock at a price of $1.25 per share.

  

Vehicles and Equipment Notes Payable

 

The Company has one note payable relating to the purchase of a Company vehicle as of January 31, 2022. The balance outstanding under the note payable was $ i 20,956 as of January 31, 2022. The note payable bears interest of  i 5.99% with principal and interest due monthly. The note matures in September 2023. The Company had the same note payable relating to the purchase of a Company vehicle as of April 30, 2021 with a balance outstanding of $ i 40,474.

 

The Company’s future minimum principal payments as of January 31, 2022 are as follows:

 

 i 
Schedule of future minimum debt payments     
2022  $ i 4,158 
2023    i 16,798 
 Total future minimum payment  $ i 20,956 
 / 

  

Other Notes Payable

 

On May 8, 2020, the Company received $ i 100,344 from the Paycheck Protection Program. This PPP loan has a two-year term and bears interest at a rate of  i 1% per annum and does not require collateral. The loan was fully forgiven in November of 2020 by the SBA and a gain on extinguishment of debt of $ i 100,344 was recorded within other income during the year ended April 30, 2021.

 

On February 1, 2021, the Company received $ i 50,000 from an investor and in turn issued a promissory note with an  i 8% interest rate, with collateral of 8 drag slat application units, and is to be paid in full by  i February 28, 2022. During the year ended April 30, 2021, the Company had paid $ i 666 in interest for this note. A payment of $ i 5,225 was made during the nine month period ending January 31, 2022. During the period ended January 31, 2022, the outstanding debt was used as proceeds for stock option exercises of  i 33,000 shares of stock.

 

On February 11, 2021, WSC received $ i 40,625 from the Paycheck Protection Program. The PPP Loan has a five-year term and bears interest at a rate of  i 1% per annum and does not require collateral. Monthly principal and interest payments are deferred for ten months after the date of disbursement. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. WSC has not yet applied for forgiveness but believes it will be forgiven.

 

On February 14, 2021, ICS received $ i 48,510 from the Paycheck Protection Program. The PPP Loan has a five-year term and bears interest at a rate of  i 1% per annum and does not require collateral. Monthly principal and interest payments are deferred for ten months after the date of disbursement. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. ICS has not yet applied for forgiveness but believes it will be forgiven.

 

 

 

 

 C: 
 13 

 

 

On March 16, 2021, SPE received $ i 15,657 from the Paycheck Protection Program. The PPP Loan has a five-year term and bears interest at a rate of  i 1% per annum and does not require collateral. Monthly principal and interest payments are deferred for ten months after the date of disbursement. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. SPE has not yet applied for forgiveness but believes it will be forgiven.

  

On April 19, 2021, the Company received $ i 50,000 from an investor and in turn issued a promissory note with an  i 8% interest rate. This note does not require collateral and is to be paid in full by  i May 19, 2022. No payments have been made at this time. During the nine-month period ended January 31, 2022, the outstanding debt was used as proceeds for stock option exercises of  i 250,000 shares of stock.

 

On May 10, 2021, the Company received $ i 25,000 from an investor and in turn issued a promissory note with an  i 6% interest rate. This note does not require collateral and is to be paid in full by  i August 6, 2021. During the nine-month period ended January 31, 2022, the outstanding debt was used as proceeds for stock option exercises of  i 150,000 shares of stock.

 

On May 19, 2021, the Company received $ i 50,000 from an investor and in turn issued a promissory note with an  i 8% interest rate. This note does not require collateral and is to be paid in full by  i May 19, 2022. During the nine-month period ended January 31, 2022, the outstanding debt was used as proceeds for stock option exercises of  i 250,000 shares of stock.

 

On June 7, 2021, the Company received $ i 26,000 from an investor and in turn issued a promissory note with an  i 6% interest rate. This note does not require collateral and is to be paid in full by  i August 7, 2021. During the nine-month period ended January 31, 2022, the outstanding debt was used as proceeds for stock option exercises of  i 150,000 shares of stock.

 

On June 7, 2021, the Company received $ i 20,000 from another investor and in turn issued a promissory note with an  i 6% interest rate. This note does not require collateral and is to be paid in full by  i August 7, 2021. During the nine-month period ended January 31, 2022, the outstanding debt was used as proceeds for stock option exercises of  i 30,000 shares of stock. During the nine-month period ended January 31, 2022, the Company had accrued $ i 20,000 in unpaid interest for promissory notes that were also used as proceeds for stock option exercises of 5,000 shares of stock.

 

 / 
 i 

4. ACCRUED EXPENSES

 

Accrued expenses, consisting primarily of accrued salaries for officers and executive management, include the following balance at January 31, 2022 and April 30, 2021:

 

 i 
Schedule of accrued expenses        
   January 31,
2022
   April 30,
2021
 
Accrued Compensation  $ i 1,164,013   $ i 934,104 
Other Accrued Expenses    i 513,693     i 267,464 
 Accrued expenses  $ i 1,677,706   $ i 1,201,568 
 / 

 

 / 
 i 

5. COMMITMENTS, CONTINGENCIES AND CONCENTRATIONS

 

Leases

 

As of January 31, 2022, the weighted average remaining lease term and weighted average discount rate for financing leases was  i 2.2 years and  i 3.99%, respectively. The Company's future financing lease obligations that have not yet commenced are immaterial. For nine-month period January 31, 2022 and January 31, 2021, the Company's cash paid for financing leases was $ i 40,248 and $ i 22,950. For the three-month period January 31, 2022 and 2021, the Company paid $ i 13,414 and $ i 0 for financing leases.

 

 

 

 

 C: 
 14 

 

 

The Company’s undiscounted annual future minimum lease payments as of January 31, 2022 consist of:

 

 i 
Schedule of future minimum lease payments     
2022  $ i 56,105 
2023    i 142,902 
2024    i 65,962 
2025    i 28,076 
2026    i 13,994 
Total lease payments    i 307,038 
Interest   ( i 23,709)
Present value of lease liabilities  $ i 283,329 
 / 

 

Concentrations

 

As of January 31, 2022, the Company had three customers which made up  i 60% of the outstanding accounts receivable balance. As of April 31, 2021, the Company had four customers which made up  i 63% of the outstanding accounts receivable balance.

 

For the nine months ended January 31, 2022, the Company had two customers which made up  i 50% of total revenues. For the nine months ended January 31, 2021, the Company had two customers which made up  i 48% of total revenues. For the three months ended January 31, 2022, the Company had three customers which made up  i 64% of total revenues. For the three months ended January 31, 2021, the Company had two customers which made up  i 46% of total revenues.

  

 / 
 i 

6. STOCKHOLDERS’ EQUITY

 

Common Stock and Preferred Stock

 

As of January 31, 2022, and 2021, the authorized share capital of the Company consisted of 75,000,000 shares of common stock, $0.0001 par value. No other classes of stock are authorized.

  

Common Stock

 

For the nine months ended January 31, 2022, the Company sold  i 300,000 shares at $ i 0.33 per share for $ i 100,000 in cash proceeds,  i 400,000 shares at $ i .50 per share for $ i 150,000 in cash proceeds and $ i 50,000 in an assigned note receivable, and  i 850,000 shares at $ i 0.25 per share for total cash proceeds of $ i 162,550. Of the 1.55 million shares of stock,  i 900,000 shares have been issued, and  i 650,000 shares of stock have yet to be issued. For the nine months ended January 31, 2021, the Company has  i 36,250 common shares repurchased at $ i 1.25 per share for a total cash payment amount of $ i 45,313 including interest.

 

Warrants

 

During the nine months ended January 31, 2022 and 2021, there were  i 0 warrants exercised.

 

For the three months ended January 31, 2022 and 2021, the Company had no sale or repurchase of warrants.

 

As of January 31, 2022, and April 30 2021, there were  i  i 82,668 /  common stock warrants outstanding, respectively, with an exercise price of $0.50.

 

 

 

 

 C: 
 15 

 

 

Stock option plan

 

Effective February 1, 2017, the Company established the 2016 Stock Option Plan (the “Plan”). The Board of Directors of the Company has the authority and discretion to grant stock options. The maximum number of shares of stock that may be issued pursuant to the exercise of options under the Plan is  i 10,000,000. Eligible individuals include any employee or director of the Company and any consultant providing services to the Company. The expiration date and exercise price for each stock option grant are as established by the Board of Directors of the Company. No option may be issued under the Plan after February 1, 2027. On March 18, 2018, the Plan was amended to increase the maximum number of shares of stock that may be issued to 5,000,000. On July 10, 2018, the Plan was amended to increase the maximum number of shares of stock that may be issued to 5,500,000. In November of 2019, the Plan was further amended to increase the shares of stock that may be issued to 10,000,000.

 

During the nine months ended January 31, 2022 and 2021, there were  i 5,073,020 and  i 0 common stock options granted.  i 3,223,020 options granted have an exercise price of $0.25 and vested immediately. The remaining  i 1,850,000 have an exercise price of $ i 0.25 and vest over a two-year period with each quarter vesting six-months after the grant date.

 

Stock option activity during the nine-month period ended January 31, 2022 is summarized as follows:

 

 i 
Schedule of option activity                
  

Shares

Under Option

   Price Per Share   Weighted
Average
Exercise Price
   Weighted
Average
Remaining
Contractual Life
 
                 
Outstanding - beginning of period    i 7,289,750    $0.00 - 1.79   $ i 1.31     i 113 months 
Granted    i 5,073,020    0.25     i 0.25     i 108 months 
Exercised   ( i 1,383,020)        i      
Canceled or expired    i          i      
Outstanding - end of period    i 10,979,750    $0.00 - 1.50   $ i 0.94     i 106 months 
                     
Exercisable - end of period    i 8,984,750        $ i 0.84     i 89 months 
 / 

  

Stock option activity during the nine-month period ended January 31, 2021, is summarized as follows:

 

  

Shares

Under Option

   Price Per Share  

Weighted

Average

Exercise Price

  

Weighted

Average

Remaining

Contractual Life

 
                 
Outstanding - beginning of period    i 7,309,750    $0.00 - 1.50   $ i 1.18     i 113 months 
Granted                
Exercised                
Canceled or expired                
Outstanding - end of period    i 7,309,750    $0.00 - 1.50   $ i 1.12     i 99 months 
                     
Exercisable - end of period    i 6,569,750        $ i 0.92     i 86 months 

 

 

 

 

 C: 
 16 

 

 

The fair value of each option grant is calculated using the following assumptions:

 

 i 
Schedule of fair value assumption      
  January 31,   January 31,
2022   2021
Expected life – years  i 6   NA
Interest rate  i 1.58- i 1.89%   NA
Volatility  i 72.7%   NA
Dividend yield  i -%    i %
 / 

 

Total share-based compensation expense (including stock grants) included in salaries and wages was $ i 396,954 and $ i 44,553 for the nine months ended January 31, 2022 and 2021, respectively. Total share-based compensation expense (including stock grants) included in salaries and wages was $ i 239,915 and $ i 44,553 for the three months ended January 31, 2021 and 2020, respectively. Unamortized share-based compensation expense amounted to $ i 148,510, which is expected to be recognized over the next 10 months as of January 31, 2022.

 

 / 
 i 

7. RELATED PARTY TRANSACTIONS

 

During the nine months ended January 31, 2022 and 2021, the Company incurred consulting fees of $ i 122,829 and $ i 214,487 to five separate entities owned by five current shareholders. An additional $ i 108,000 and $ i 74,000 in consulting fees were incurred by the Company from an entity owned by the spouse of the CEO during the nine months ended January 31, 2022 and 2021, respectively. The total related party consulting fees unpaid balance due was $ i 108,000 and $ i 62,693 as of January 31, 2022 and 2021, respectively, and is included in accounts payable in the accompanying consolidated financial statements.

 

During the three months ended January 31, 2022 and 2021, the Company incurred consulting fees of $ i 53,863 and $ i 62,693 to four separate entities owned by four current shareholders. The total related party consulting fees unpaid balance due was $ i 32,863 and $ i 30,741 as of January 31, 2022 and 2021, respectively, and is included in accounts payable in the accompanying consolidated financial statements.

 

Two separate related parties are allowing the Company to rent vehicles for a monthly fee of $1,650 and $1,243. For the nine months ended January 31, 2022, the Company paid a total of $ i 14,850 and $ i 11,187. For the three months ended January 31, 2022, the Company paid a total of $ i 4,950 and $ i 3,729. For the nine months ended January 31, 2021, the Company paid a total of $ i 12,875 and $ i 9,690. For the three months ended January 31, 2021, the Company paid a total of $ i 4,950 and $ i 3,729.

 

 / 
 i 

8. INCOME TAXES

 

For the nine months ended January 31, 2022 and 2021, the effective tax rate of 0% varies from the U.S. federal statutory rate primarily due to net losses and the valuation allowance associated with the net operating loss carryforwards. The Company continually reviews the realizability of its deferred tax assets, including an analysis of factors such as future taxable income, reversal of existing taxable temporary differences, and tax planning strategies. The Company continues to record a full valuation allowance against its net deferred tax assets. The Company assessed whether a valuation allowance should be established against its deferred tax assets based on consideration of all available evidence, using a “more likely than not” standard. In assessing the need for a valuation allowance, the Company considered both positive and negative evidence related to the likelihood of realization of deferred tax assets. In making such assessment, more weight was given to evidence that could be objectively verified, including recent cumulative losses. Future sources of taxable income were also considered in determining the amount of the recorded valuation allowance. Based on the Company’s review of this evidence at January 31, 2022, management determined that a full valuation allowance against all of the Company’s deferred tax assets at January 31, 2022 was appropriate.

  

 

 

 

 C: 
 17 

 

 

The following table summarizes the difference between the actual tax provision and the amounts obtained by applying the statutory tax rates to the income or loss before income taxes for the period ending January 31, 2022 and 2021:

 

 i 
Schedule of income tax reconciliation        
   January 31,
2022
   January 31,
2021
 
Tax benefit calculated at statutory rate    i 21.00%     i 21.00% 
Expense not deductible   ( i 0.05)   ( i 0.06)
Changes to valuation allowance   ( i 20.95)   ( i 20.94)
Provision for income taxes    i 0%     i 0% 
 / 

 

 / 
 i 

9. CORONA VIRUS

 

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic has significantly impacted the economic conditions in the U.S., accelerating during the first half of March, as federal, state and local governments react to the public health crisis, creating significant uncertainties in the U.S. economy. In March 2020, we noticed a strong decline in orders from our customers, as businesses around the country began to cease their operations due to COVID-19. In an attempt to mitigate the ongoing impact of the pandemic on our cash flows certain actions were taken. The actions include targeted reductions in discretionary operating expenses such as advertising and payroll expenses, reducing capital expenditures, and reducing travel for business development purposes.

 

The Paycheck Protection Program (“PPP”) provides loans from the U.S. Small Business Administration (“SBA”) to help businesses keep their workforce employed during the Coronavirus (COVID-19) crisis. SBA will forgive loans if all employees are kept on the payroll for eight weeks and the money is used for payroll, rent, mortgage interest, or utilities. On May 8, 2020, the Company received a PPP loan in the amount of $ i 100,344. The loan was fully forgiven in November of 2020.

 

On February 11, 2021, WSC received $ i 40,625 from the Paycheck Protection Program. The PPP Loan has a five-year term and bears interest at a rate of  i 1% per annum and does not require collateral. Monthly principal and interest payments are deferred for ten months after the date of disbursement. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. WSC has not yet applied for forgiveness but believes it will be forgiven.

 

On February 14, 2021, ICS received $ i 48,510 from the Paycheck Protection Program. The PPP Loan has a five-year term and bears interest at a rate of  i 1% per annum and does not require collateral. Monthly principal and interest payments are deferred for ten months after the date of disbursement. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. ICS has not yet applied for forgiveness but believes it will be forgiven.

 

On March 16, 2021, SPE received $ i 15,657 from the Paycheck Protection Program. The PPP Loan has a five-year term and bears interest at a rate of  i 1% per annum and does not require collateral. Monthly principal and interest payments are deferred for ten months after the date of disbursement. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. SPE has not yet applied for forgiveness but believes it will be forgiven.

 

Continued impacts of the pandemic have had a material adverse impact on our revenues, earnings, liquidity and cash flows, and may require additional actions in response, including, but not limited to, employee layoffs, reduced production, or further expense reductions, all in an effort to mitigate such impacts. The extent of the impact of the pandemic on our business and financial results will depend largely on future developments, including the duration of the spread of the outbreak within the U.S., and the related /impact on consumer confidence and spending, all of which are highly uncertain and cannot be predicted. This situation is rapidly changing and additional impacts to the business may arise that we are not aware of currently. While the disruption is currently expected to be temporary, there is uncertainty around the duration. The ultimate impact of the pandemic on the Company’s results of operations, financial position, liquidity, or capital resources cannot be reasonably estimated at this time.

  

 

 

 

 C: 
 18 

 

 

 / 
 i 

11. SUBSEQUENT EVENTS

 

On March 3, 2022, the Company issued 300,000 shares of stock at $0.15 per share for a total cash amount of $45,000.

 

On March 15, 2022, the Company issued 180,000 shares of stock at $0.15 per share for a total cash amount of $45,000.

 

 On April 1, 2022, the Company received $76,000 from an investor and in turn issued a promissory note with an 21% interest rate. This note does not require collateral. Two payments of $1,768 were made during the period ended April 30, 2022.

 

On April 6, 2022, the Company issued 60,000 shares of stock at $0.25 per share for a total cash amount of $15,000.

 

On April 12, 2022, the company received $25,000 from another investor and in turn issued a promissory note with an 21% interest rate. This note does not require collateral. No payments were during the period ended April 30, 2022.

 

On May 12, 2022, Mr. Paul Williams, a member of the Board of Directors of Lux Amber Corp., tendered his resignation as a Board member, and as Vice Chairman and Chief Financial Officer. Mr. Williams will continue to serve the Company for a transition period.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 C: 
 19 

 

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with its unaudited interim condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the fiscal year ended April 30, 2021.

 

FORWARD-LOOKING STATEMENTS

 

The discussion contained herein contains "forward-looking statements" that involve risk and uncertainties. These statements may be identified by the use of terminology such as "believes," "expects," "may," "should" or anticipates" or expressing this terminology negatively or similar expressions or by discussions of strategy. The cautionary statements made in this Form 10-Q should be read as being applicable to all related forward-looking statements wherever they appear in this Form 10-Q. The Company’s actual results could differ materially from those discussed in this report.

 

BUSINESS AND PLAN OF OPERATION

 

Lux Amber, Corp., based in Dothan, Alabama, is an international specialty chemical company with many products that are friendly to the environment. The common description is “green chemicals.” The Company has degreed chemists on staff with years of successful experience in the specialty chemical industry. The term “specialty chemicals” is best defined by those chemicals whose formulas allow the chemical compounds to perform a specific function for a class of customers. The Company’s products have been used successfully in a diverse array of applications, including:

 

  · Chemicals to protect surfaces in asphalt handling equipment

 

  · Chemicals to control the reproduction of pests

 

  · Military Chemical, Biological, Radiological, Nuclear, and Explosives (CBRNE) sites

 

  · Commercial nuclear power plants and nuclear-powered ships

 

  · Hazardous toxic industrial chemical and toxic industrial material clean-up

  

The Company’s corporate telephone number is 214-676-5475. The Company’s stock symbol is LXAM.

 

LAC has three (3) wholly owned subsidiaries (collectively with LAC, the “Company”): Worldwide Specialty Chemicals, Inc. (“WSC”), Industrial Chem Solutions, Inc. (“ICS”), and Safeway Pest Elimination, LLC, (“SPE”), which was formed July 16, 2018. LAC and its subsidiaries serve as both producers and distributors of environmentally safe, specialty chemicals.

 

The Company’s products utilize all-natural and renewable resources, contain no dangerous chemicals or additives, and offer “green” solutions to its customers. ICS’ product line includes asphalt release agents, industrial cleaners, environmental remediation gels, odor control agents, and consumer friendly cleaners for a wide range of uses, including construction, environmental remediation, hazardous materials clean-up, nuclear decommissioning, industrial cleaning, and odor control. SPE’s products are designed for the elimination and control of pests.

 

LIQUIDITY AND CAPITAL RESOURCES

 

During the nine-month period ended January 31, 2022, the primary sources of liquidity were cash flows from financing activities, and in particular, issuance of stock and promissory notes.

 

 

 

 

 C: 
 20 

 

 

As of January 31, 2022, the Company had total assets of $3,150,976 consisting of current assets of $93,829, which included $27,480 in cash, $45,279 in receivables, $16,103 in inventory, $4,967 in prepaid expenses and other current assets, and long-term assets of $2,309,953 in goodwill and other intangibles, $434,110 in fixed assets, $18,270 in other long-term assets, and $294,814 in right of use assets. As of April 30, 2021, the Company had total assets of $3,353,460, consisting of current assets of $112,982 in receivables, $137,211 in inventory, $7,960 in prepaid expenses and other current assets and long-term assets of $2,309,953 in goodwill and other intangibles, and $512,697 in fixed assets and $272,657 in right of use assets.

  

As of January 31, 2022, the Company had total liabilities totaling $2,974,722 including $2,354,123 in current payables and accrued expenses, $211,442 in related party payables, $21,076 notes payable, $104,752 in Paycheck Protection Program loans, and $283,329 in right of use liabilities. As of April 30, 2021, the Company had total liabilities totaling $2,468,547 including $1,756,156 in accounts payable and accrued expenses, $208,756 in related party payables, $127,624 in notes payable, and $271,259 in lease liabilities, and $104,752 in Paycheck Protection Program loans.

 

As January 31, 2022, the Company had an accumulated stockholders’ equity of $176,253 and $884,913 at April 30,2021. The decrease is result of the items discussed below.

 

RESULTS OF OPERATIONS

 

Comparison of the three and nine-month periods ended January 31, 2022 and January 31, 2021.

 

Revenues

 

For the nine-month period ended January 31, 2022, the Company had revenues of $1,112,022, and $816,598 for the same period in 2021. The increase in sales is primarily of an increase in ICS’s sales of approximately $295,424 due to an increase in selling price and new customers. The increase in the cost of goods sold is due to an increase in sales volume.

  

For the three-month period ended January 31, 2022, the Company had revenues of $248,944, and $130,183 for the same period in 2021. The increase in sales is primarily the result of an increase in ICS’s sales of approximately $118,606 due to an increase in selling price and new customers. The increase in the cost of goods sold is due to an increase in sales volume.

 

Operating Expenses

 

For the nine-month period ended January 31, 2022, the Company had total operating expenses of $2,089,921 which included $24,629 in product delivery expenses, $1,944,324 in general and administrative expenses, $11,607 in selling expenses, and $109,362 in depreciation and amortization of assets. For the nine-month period ended January 31, 2021, the Company had total operating expenses of $1,628,240 which included $404,895 in product delivery expenses, $1,038,304 in general and administrative expenses, $70,450 in selling expenses, and $114,591 in depreciation of assets. The increase in operating expenses is primarily related to 1) increase in stock compensation expense; 2) offset by lower selling expenses; 3) lower product delivery costs.

 

For the three-month period ended January 31, 2022, the Company had total operating expenses of $988,772 which included $15,475 in product delivery expenses, $874,730 in general and administrative expenses, $6,683 in selling expenses, and $91,884 in depreciation and amortization of assets. For the three-month period ended January 31, 2021, the Company had total operating expenses of $188,495 which included $103,629 in product delivery expenses, $10,547 in general and administrative expenses, $34,695 in selling expenses, and $39,624 in depreciation of assets. The increase in operating expenses is primarily related to 1) increase in stock compensation expense; 2) offset by lower selling expenses; 3) lower product delivery costs.

.

 

 

 

 C: 
 21 

 

 

GOING CONCERN

 

The accompanying consolidated financial statements are presented on a going concern basis. The Company's financial condition raises substantial doubt about the Company's ability to continue as a going concern. The Company has limited cash, its current liabilities exceed its current assets as of January 31, 2022 and has incurred reoccurring losses from operations during the nine months ended January 31, 2022. The Company is relying on capital from investors to meet the majority of its operating expenses.

  

OFF-BALANCE SHEET ARRANGEMENTS

  

There are no off-balance sheet transactions, arrangements, obligations (including contingent obligations), or other relationships with unconsolidated entities or other persons that have, or may have, a material effect on financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources of the Company.

 

ITEM 4. CONTROLS AND PROCEDURES

 

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

 

The Company’s management, with the participation of its President and Chief Executive Officer, has evaluated the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this Quarterly Report on Form 10-Q.  Based on such evaluation, the Company’s Chief Executive Officer and President have concluded that, as of such date, its disclosure controls and procedures are not effective.

 

INTERNAL CONTROL OVER FINANCIAL REPORTING

 

As indicated in the Company’s Form 10-K filed on September 30, 2021, the Company’s Principal Executive Officer and President concluded that its internal control over financial reporting was not effective during the 2021 fiscal year.

 

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

During the period covered by this report, there were no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

  

 

 

 

 

 

 

 

 

 C: 
 22 

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None.

 

ITEM 1A. RISK FACTORS

 

There have been no material changes to the risks to the Company’s business from those described in its Annual Report on Form 10-K for the fiscal year ended April 30, 2021, as filed with the SEC on September 30, 2021.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

To assist the Company to obtain and preserve working capital to support its current operations the Company entered into the following transactions:

 

On July 13, 2021, the Company sold 200,000 common shares at $0.50 per share for a total cash amount of $100,000.

 

On July 23, 2021, the Company sold 100,000 common shares at $0.50 per share for a total cash amount of $50,000.

 

On July 23, 2021, the Company sold 100,000 common shares at $0.50 per share for an assigned note receivable.

 

On September 20, 2021, the Company issued 60,000 shares at $0.33 per share for payment of $20,000 of outstanding payables.

 

On September 20, 2021, the Company issued 300,000 shares at $0.33 per share for a total cash amount of $100,000.

 

On January 11, 2022, the Company issued 683,020 shares at $0.25 per share for a payment of $235,755 of outstanding payables.

 

On January 11, 2022, the Company issued 500,000 shares at $0.15 per share for a total cash amount of $105,050.

 

During the period ending January 31, 2022, the Company received $162,500 total cash proceeds for common stock shares to be issued in March of 2022.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

 

 

 

 C: 
 23 

 

 

ITEM 6. EXHIBITS

 

Exhibit No. Description
31.1 Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of President required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2 Certification of President pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in IXBRL and included in exhibit 101).

 

 

 

 

 

 

 

 

 C: 
 24 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: May 25, 2022

 

  Lux Amber, Corp.
     
     
  By: /s/ E. Thomas Layton
    E. Thomas Layton, CEO and Director
     
  By: /s/ Walton A. Ashwander Jr.
    Walton A. Ashwander Jr., President and Director

 

 

 

 

 

 

 

 

 

 

 

 

 C: 
 25 

 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
2/1/27
Filed on:5/25/22
5/19/22
5/12/22
4/30/22
4/28/22
4/12/22
4/6/22
4/1/22
3/15/22
3/3/22
2/28/22
For Period end:1/31/22NT 10-Q
1/11/22
12/15/21
10/31/2110-Q
9/30/2110-K
9/20/21
8/7/21
8/6/21
7/23/21
7/13/21
6/7/218-K
5/19/21
5/10/21
4/30/2110-K,  5,  NT 10-K
4/19/21
3/16/21
2/14/21
2/11/21
2/1/21
1/31/2110-Q,  NT 10-Q
1/15/21
10/31/2010-Q,  NT 10-Q
9/15/20
5/8/20
4/30/2010-KT,  10-KT/A,  3,  NT 10-K
1/31/2010-Q
7/16/18
7/10/18
3/18/18
1/19/18
2/1/17
 List all Filings 
Top
Filing Submission 0001683168-22-004005   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., Apr. 24, 9:12:37.1am ET